Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients
Abstract
<jats:p>Circulating tumour DNAs and non-coding RNAs present in body fluids have been under investigation as tools for cancer diagnosis, disease monitoring, and prognosis for many years. These so-called liquid biopsies offer the opportunity to obtain information about the molecular make-up of a cancer in a minimal invasive way and offer the possibility to implement theranostics for precision oncology. Furthermore, liquid biopsies could overcome the limitations of tissue biopsies in capturing the complexity of tumour heterogeneity within the primary cancer and among different metastatic sites. Liquid biopsies may also be implemented to detect early tumour formation or to monitor cancer relapse of response to therapy with greater sensitivity compared with the currently available protein-based blood biomarkers. Most colorectal cancers are often diagnosed at late stages and have a high mortality rate. Hence, biomolecules as nucleic acids present in liquid biopsies might have prognostic potential and could serve as predictive biomarkers for chemotherapeutic regimens. This review will focus on the role of circulating tumour DNAs and non-coding RNAs as diagnostic, prognostic, and predictive biomarkers in the context of colorectal cancer.</jats:p>
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
colorectal cancer
liquid biopsy
microRNA
circularRNA
long non-coding RNA
circulating cell-free tumour DNA
biomarker
POLYMERASE-CHAIN-REACTION
CELL-FREE DNA
COLON-CANCER
STAGE-II
MOLECULAR-DETECTION
MESSENGER-RNAS
CARCINOEMBRYONIC ANTIGEN
PROGNOSTIC-SIGNIFICANCE
PREDICTS SURVIVAL
DIAGNOSTIC-VALUE
Research team
Gastrointestinal Cancer Biology and Genomics
Gastrointestinal Cancer Biology and Genomics
Language
eng
Date accepted
2020-07-21
License start date
2020-09-01
Citation
GASTROINTESTINAL DISORDERS, 2020, 2 (3), pp. 212 - 235 (24)
Publisher
MDPI